Connecticut Capital Management Group’s Protagonist Therapeutics PTGX Stock Holding History

Connecticut Capital Management Group’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$213K	Buy	+1,736	New	+$181K	0.17%	121

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Connecticut Capital Management Group's PTGX Position: Q2 2026 in Review

Connecticut Capital Management Group opened a new position in Protagonist Therapeutics (PTGX) in Q2 2026: 1,736 shares worth $213K. The stake represents 0.17% of the portfolio and ranks #121 among its holdings.

341 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Connecticut Capital Management Group held 1,736 shares of Protagonist Therapeutics worth $213K as of Q2 2026.
Protagonist Therapeutics was a new Connecticut Capital Management Group position in Q2 2026.
Protagonist Therapeutics made up 0.17% of Connecticut Capital Management Group's portfolio in Q2 2026, its #121 holding.
341 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Connecticut Capital Management Group's 13F filing for Q2 2026, filed 20 Jul 2026.